Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous infliximab monotherapy versus subcutaneous infliximab plus immunosuppression in moderate to severe Crohn's disease
NL-OMON54347Phase 4Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of infliximab, mercaptopurine, azathioprine, tioguanine and methotrexate in Crohn's disease and inflammatory bowel disease (IBD), sponsored by Amsterdam University Medical Center. Started Nov 2021; status: recruiting.
02
Drugs
infliximabmercaptopurineazathioprinetioguaninemethotrexate
03
Conditions
Crohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON54347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54347.